Spots Global Cancer Trial Database for Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma
Official Title: Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma Progressed After Immune Checkpoint Inhibitors:a Single-arm,Open-label Prospective Trial
Study ID: NCT04948125
Conditions
Study Description
Brief Summary: This study is a phase II study, to evaluate the effectiveness and safety of Camrelizumab combined with apatinib for advanced gastric or esophagogastric adenocarcinoma progressed after immune checkpoint inhibitors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Henan cancer hospital/The affiliated Cancer Hospital of ZhengZhou university, Henan, , China
Contact Details
Name: Ying Liu
Affiliation: Henan Cancer Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
